PDT Partners LLC Buys New Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)

PDT Partners LLC bought a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 60,669 shares of the biopharmaceutical company's stock, valued at approximately $1,419,000.

A number of other large investors have also made changes to their positions in TGTX. Captrust Financial Advisors boosted its stake in TG Therapeutics by 21.1% during the third quarter. Captrust Financial Advisors now owns 30,327 shares of the biopharmaceutical company's stock worth $709,000 after buying an additional 5,279 shares during the last quarter. Public Sector Pension Investment Board purchased a new position in shares of TG Therapeutics during the 3rd quarter worth $6,619,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of TG Therapeutics by 12.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 31,147 shares of the biopharmaceutical company's stock valued at $729,000 after acquiring an additional 3,347 shares during the last quarter. Harvest Fund Management Co. Ltd purchased a new stake in shares of TG Therapeutics in the third quarter valued at about $111,000. Finally, Penserra Capital Management LLC increased its position in TG Therapeutics by 293.6% during the third quarter. Penserra Capital Management LLC now owns 98,144 shares of the biopharmaceutical company's stock worth $2,295,000 after purchasing an additional 73,211 shares during the last quarter. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

TG Therapeutics Trading Up 0.8 %

Shares of TGTX traded up $0.29 during midday trading on Monday, hitting $35.09. 2,209,749 shares of the stock were exchanged, compared to its average volume of 3,669,428. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The firm has a market cap of $5.46 billion, a P/E ratio of -347.97 and a beta of 2.19. TG Therapeutics, Inc. has a 52-week low of $12.84 and a 52-week high of $36.84. The stock has a fifty day simple moving average of $26.59 and a 200 day simple moving average of $22.32.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.01). The firm had revenue of $83.90 million during the quarter, compared to analyst estimates of $81.68 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business's revenue was down 49.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.73 earnings per share. On average, research analysts anticipate that TG Therapeutics, Inc. will post 0.17 EPS for the current fiscal year.

Insiders Place Their Bets

In other TG Therapeutics news, Director Sagar Lonial sold 5,000 shares of the company's stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $30.44, for a total transaction of $152,200.00. Following the sale, the director now owns 100,195 shares in the company, valued at $3,049,935.80. This represents a 4.75 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 10.50% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on TGTX shares. JPMorgan Chase & Co. boosted their target price on shares of TG Therapeutics from $30.00 to $43.00 and gave the company an "overweight" rating in a report on Monday, November 25th. TD Cowen assumed coverage on TG Therapeutics in a report on Tuesday, October 29th. They issued a "buy" rating and a $50.00 price objective on the stock. HC Wainwright raised their target price on TG Therapeutics from $49.00 to $55.00 and gave the stock a "buy" rating in a research note on Tuesday, November 5th. The Goldman Sachs Group upped their price target on TG Therapeutics from $20.00 to $22.00 and gave the company a "neutral" rating in a research note on Tuesday, November 5th. Finally, B. Riley raised their price objective on TG Therapeutics from $29.00 to $34.00 and gave the stock a "buy" rating in a research report on Wednesday, August 7th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $40.67.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.